DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2999
+0.0349 (+13.17%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close0.2650
Open0.2700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2550 - 0.3090
52 Week Range0.2550 - 1,050.0000
Volume175,697
Avg. Volume158,555
Market Cap2.701M
Beta (3Y Monthly)-0.04
PE Ratio (TTM)N/A
EPS (TTM)-79.6390
Earnings DateMar 23, 2017 - Mar 24, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Delcath Announces Third Quarter Fiscal 2018 Financial Results

    NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces.

  • GlobeNewswire28 days ago

    Delcath Announces Enrollment of First Patient in ALIGN Trial

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that patient treatments have begun in the Company’s second global US registration trial investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in the treatment of patients with intrahepatic cholangiocarcinoma (ICC). The University of Tennessee Health Science Center (UTHSC) in collaboration with Methodist University Hospital (MUH) and West Cancer Center (WCC) in Memphis, Tennessee have enrolled the trial’s first patient and treatments have begun by a team led by Dr. Evan S. Glazer.

  • GlobeNewswirelast month

    Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amended trial protocol for the company’s registration trial in ocular melanoma liver metastases.

  • GlobeNewswirelast month

    Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been published in the journal European Radiology. The study is the first analysis on the use of Delcath’s PHP® Therapy for the treatment of ICC. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France with Dr. Steffen Marquardt of Hannover Medical School serving as lead author.

  • GlobeNewswire2 months ago

    Delcath Raises $8.1 Million from Shareholders in Rights Offering

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces the closing of the subscription period of its previously announced rights offering. The rights offering was made pursuant to a Registration Statement on Form S-1 that was made effective on August 3, 2018. At the end of the subscription period on September 26, 2018, Delcath had received 4,249,604 basic subscriptions and 418,207 oversubscriptions for a total of 4,667,811 subscriptions, each subscription for one share of its Common Stock.

  • GlobeNewswire2 months ago

    Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective study conducted by Leiden University Medical Center (LUMC) in The Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, were presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting this week.

  • GlobeNewswire2 months ago

    Data on Delcath’s PHP Therapy presented at CIRSE 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that data from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, was presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. The study entitled Survival and Response of Patients with Metastatic Ocular Melanoma after Chemosaturation Percutaneous Hepatic Perfusion was conducted by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.

  • GlobeNewswire2 months ago

    Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights will be exercisable until 5:00 p.m. Eastern time on September 26, 2018, though most broker dealers will require holders of rights to exercise in advance of this date. Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock.

  • GlobeNewswire2 months ago

    Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been accepted for publication in the journal European Radiology. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicenter Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France.  The results have been previously presented to a Delcath sponsored Key Opinion Leaders forum, where investigators agreed the data "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation." A summary of these findings was later presented to the Cholangiocarcinoma Foundation 2017 annual meeting and have provided a basis for the protocol design for the Company’s registration trial in ICC, which has commenced.  Data from this analysis is embargoed until publication.

  • GlobeNewswire3 months ago

    Delcath Announces Extension of Rights Offering Period to September 26, 2018

    Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an additional 30-day period, until 5:00 PM Eastern time on September 26, 2018. Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.  In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

  • GlobeNewswire3 months ago

    Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for presentation as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. The abstract, Survival and Response of Patients with Metastatic Ocular Melanoma after Chemosaturation Percutaneous Hepatic Perfusion, will be presented by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.

  • GlobeNewswire3 months ago

    Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 clinical trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from the prior randomized protocol for the FOCUS Trial.

  • GlobeNewswire3 months ago

    Delcath Announces Pending Expiration to Rights Offering Subscription Period

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday August 27, 2018, of the subscription period for its previously announced rights offering that began on Tuesday, August 7, 2018.  The Company also reminds holders of rights that most broker/dealers require clients to place orders in advance of the official expiration date of August 27, 2018 so that holders of rights should confirm with their broker/dealers directly in order to enable timely participation. Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock.

  • GlobeNewswire3 months ago

    First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its registration trial in ocular melanoma liver metastases. The trial, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma (The FOCUS Trial), will enroll a minimum of 80 patients with ocular melanoma metastatic to the liver. “We are very pleased that the team at Stanford were able to begin enrolling patients in the amended trial so quickly,” said Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems.

  • GlobeNewswire3 months ago

    Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that patient enrollment has begun under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to obtain Institutional Review Board (IRB) approval for the amended protocol and the center is open to patient enrollment.